Latest News
AstraZeneca secures US approval for Imfinzi–BCG regimen in high‑risk bladder cancer
...
Samsung Bioepis launches OPUVIZ across Europe for ophthalmic conditions
29 May 2026 - South Korean biopharmaceutical company Samsung Bioepis Co Ltd announced on Friday the launch of OPUVIZ (aflibercept) 40 mg/mL solution for injection in a vial across Europe.OPUVIZ, an aflibercept biosimilar referencing Regeneron Pharmac...
Whitehawk Therapeutics to present at Jefferies 2026 Global Healthcare Conference
29 May 2026 - Clinical-stage oncology therapeutics company Whitehawk Therapeutics Inc (Nasdaq:WHWK) announced on Thursday that its president and CEO, Dave Lennon, PhD, will present at the Jefferies 2026 Global Healthcare Conference in New York City, ...
Innovent Biologics and Pfizer agree global collaboration to develop innovative oncology medicines
29 May 2026 - Chinese biopharmaceutical company Innovent Biologics Inc (HK:01801) and US-based pharmaceutical company Pfizer Inc (NYSE:PFE), have announced on Thursday that they have entered into a strategic global licensing and collaboration agreeme...
FDA approves TREMFYA label expansion
29 May 2026 - Pharmaceutical company Johnson & Johnson (J&J) (NYSE:JNJ) announced on Thursday that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to include evidence in the TREMFYA (...